Foresee Pharmaceuticals is a clinical-stage pharmaceutical company.In June 2023, Foresee Pharmaceuticals completed an underwritten public offering of 17,500,000 shares of its common stock to the public at a price of $75 per share.In December 2020 Foresee pharmaceuticals announced that it completed an underwritten public offering of 15,000,000 shares of its common stock.In March 2017, the company completed the US $16 million financing in issuance of 8 million common shares.In March 2016, the company applied for registration on Emerging Stock Market in Taiwan.In February 2016, the company closed TWD 484 million ($14.9 million) of series D funding.In January 2016, the company received the 'go public' approval from Taiwan authorities with stock ticker '6576'